Your email address is safe with us. View our Privacy policy.
FDA wants warnings on antipsychotic drugs
The FDA said it will require pharmaceutical companies to make safety-related changes to prescribing information and labeling to warn about an increased risk of death associated with the off-label use of the drugs when used to treat behavioral problems in older people with dementia.
In 2005, the FDA announced similar labeling changes for "atypical" or newer antipsychotic drugs. The warning will now cover older types of "conventional" antipsychotics.
The warning for both classes of drugs will say clinical studies indicate antipsychotic drugs of both types are associated with an increased risk of death when used in elderly patients being treated for dementia-related psychosis.
The drugs are FDA-approved primarily for the treatment of symptoms associated with schizophrenia. The decision to use antipsychotic medications in the treatment of patients with symptoms of dementia is left to the discretion of the physician. Such use is called "off-label" use and falls within the practice of medicine.
The new action includes such drugs as Compazine, Haldol, Loxitane, Mellaril, Moban, Prolixin, Thorazine and Trilafon.
Copyright 2008 by United Press International
This news arrived on: 06/16/2008
Printer Friendly Version | Send this page to a friend | Post Comment
Rate This Story:
Great - 5 - 4 - 3 - 2 - 1 - Bad
Posted Comments:
Comment archive | Comment FAQ's
 |
 |
View Science & Technology ezine stories by date or visit the complete archive |
The ArcaMax Politics channel is one of 70 content categories offered by ArcaMax Publishing on this ... |
Body Mass
